Alto Neuroscience Sued for Securities Law Violations; Investors Have Until September 19, 2025 to Discuss Rights

Alto Neuroscience, Inc. is being sued for securities law violations, with a class action lawsuit alleging that the company made false statements and/or concealed the effectiveness of its product pipeline, ALTO-100, in treating major depressive disorder. Investors who purchased Alto common stock or securities between February 2, 2024, and October 22, 2024, may be eligible to share in any recovery. The deadline to request appointment as lead plaintiff is September 19, 2025.

New York, NY – July 2, 2025 – Alto Neuroscience, Inc. (NYSE: ANRO) is facing a class action lawsuit alleging securities law violations. The lawsuit, filed by investors, claims that the company made false statements and concealed the effectiveness of its product pipeline, ALTO-100, in treating major depressive disorder.

Case Details

The lawsuit, brought by Bernstein Liebhard LLP, alleges that Alto Neuroscience misrepresented the clinical, regulatory, and commercial prospects of ALTO-100. According to the complaint, the company overstated the effectiveness of ALTO-100, leading investors to believe that the drug was more effective than it actually was. This misrepresentation, the lawsuit claims, resulted in an overestimation of the company's business and financial prospects, and therefore, its public statements were materially false and misleading.

Eligibility and Deadline

Investors who purchased Alto common stock or securities between February 2, 2024, and October 22, 2024, may be eligible to join the class action lawsuit. The deadline to request appointment as lead plaintiff is September 19, 2025.

No Cost to Participate

Participation in the lawsuit is free. There are no out-of-pocket costs or fees for class members. The law firms representing the class, Bernstein Liebhard LLP and Levi & Korsinsky, LLP, will handle all costs and expenses.

Regulatory Momentum and Financials

Despite the lawsuit, Alto Neuroscience has seen regulatory momentum with its NRX-100 candidate, a ketamine-based therapy for suicidal depression. NRX-100 has received Fast Track and CNPV designations from the FDA, which could significantly reduce its review period. Clinical trials have shown promising results, with a 55% response rate in reducing suicidality.

References

[1] Bernstein Liebhard LLP. (2025, August 18). Shareholder Alert: Bernstein Liebhard LLP Announces a Securities Fraud Class Action Lawsuit Has Been Filed Against Alto Neuroscience, Inc. NYSE: ANRO. Retrieved from https://www.globenewswire.com/news-release/2025/08/18/3134986/0/en/SHAREHOLDER-ALERT-Bernstein-Liebhard-LLP-Announces-A-Securities-Fraud-Class-Action-Lawsuit-Has-Been-Filed-Against-Alto-Neuroscience-Inc-NYSE-ANRO.html

[2] Levi & Korsinsky, LLP. (2025, August 19). Alto Neuroscience, Inc. Securities Lawsuit. Retrieved from https://www.prnewswire.com/news-releases/alto-neuroscience-inc-sued-for-securities-law-violations--investors-should-contact-levi--korsinsky-before-september-19-2025-to-discuss-your-rights--anro-302532534.html